| Document |
Document Title |
|
WO/2022/166796A1 |
Disclosed are a novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor, a preparation method therefor and use thereof. The novel pyrimidine/pyridine and heterocyclic adenosine receptor inhibitor is a compound as represen...
|
|
WO/2022/166468A1 |
A heterocyclic compound that acts as a BTK inhibitor, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a compound represented by general formula (I) and a pharmaceutica...
|
|
WO/2022/166817A1 |
Disclosed are a heterocyclic compound, and an intermediate thereof, a preparation method therefor and the use thereof. Namely, provided are a heterocyclic compound as shown in formula I-a, and a tautomer and a pharmaceutically acceptable...
|
|
WO/2022/168115A1 |
The present invention provides a process for the preparation of Larotrectinib or its pharmaceutically acceptable salts with a key intermediate of Formula IV by using Formula IIa.
|
|
WO/2022/166866A1 |
A class of macrocyclic compounds containing a dihydropyrazine and pyrazine structure, and, in particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/169798A2 |
The present disclosure relates to novel compounds that degrade Bruton's tyrosine kinase (BTK), pharmaceutical compositions containing such compounds, and their use in prevention and treatment of conditions modulated by BTK.
|
|
WO/2022/167438A1 |
The present invention relates to a compound of formula (I) wherein R1 represents H, (C1-C6)alkyl-; hydroxy-(C1-C6)alkyl-; NH2-(C1-C6)alkyl-; NH-(C1-C6)alkyl-(C1-C6)alkyl-; N((C1-C6)alkyl)2-(C1-C6)alkyl-; (C2-C6)alkenyl-; (C2-C6)alkynyl-;...
|
|
WO/2022/169921A1 |
The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said comp...
|
|
WO/2022/166920A1 |
The present invention relates to a pyrrolopyridazine compound as represented by a formula (I) or a pharmaceutically acceptable salt thereof, and also relates to a pharmaceutical preparation, a pharmaceutical composition and the use there...
|
|
WO/2022/166970A1 |
Provided in the present invention are a proteolysis targeting chimera, and a preparation method therefor and a pharmaceutical composition and the use thereof. Specifically, the proteolysis targeting chimera comprises the following struct...
|
|
WO/2022/166799A1 |
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
|
|
WO/2022/166778A1 |
A pharmaceutical composition of a capsid protein inhibitor and a preparation method thereof. Specifically, provided is a composition, comprising (S)-N5-(3,4-difluorophenyl)-6-methyl-N3-((R)-1,1,1-trifluoro
propan-2-yl)-6,7-dihydro-[1,2,3...
|
|
WO/2022/166610A1 |
Provided are a pyridazinone heterocyclic compound, a preparation method therefor and the use thereof. Specifically, provided are a compound, as represented by formula I, or a pharmaceutically acceptable salt, stereoisomer, tautomer, poly...
|
|
WO/2022/169758A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally re...
|
|
WO/2022/166844A1 |
Tricyclic compounds of formula (I), pharmaceutical compositions comprising same, methods for preparing same, and uses thereof, wherein each variable is as defined in the description.
|
|
WO/2022/169974A1 |
The present invention relates to pharmaceutical compounds, compositions, combinations, and methods, especially as they are related to compositions and methods for the treatment and/or prevention of conditions such as gout that are associ...
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2022/166923A1 |
A phenyldihydropyrimidine compound as represented by formula I, a tautomer or a pharmaceutically acceptable salt thereof. The phenyldihydropyrimidine compound has a good anti-HBV activity and can be used for preparing drugs for treating ...
|
|
WO/2022/166469A1 |
A heterocyclic compound as a fibroblast growth factor receptor (FGFR) inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula...
|
|
WO/2022/170200A1 |
The present invention refers to l-(2-sulfonyl-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl]-ethanone derivatives of formula (I) as pyruvate kinase (PKR) and/or PKM2 activators for use in the treatment of sickle cell disease, sickle cell an...
|
|
WO/2022/168956A1 |
This compound represented by the following general formula has excellent light emitting properties. Ar1 represents a benzene ring, a naphthalene ring, a phenanthrene ring, or the like, D represents a 5H-indolo[3,2,1-de]phenazin-5-yl grou...
|
|
WO/2022/166860A1 |
A compound having a structure as shown in general formula (I), a deuterated compound, a stereoisomer, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and use thereof. The compound has a good P...
|
|
WO/2022/165598A1 |
The present technology relates to an ionic plastic crystal comprising at least one delocalized anion paired with at least one cation derived from a guanidine, amidine or phosphazene organic superbase for use in electrochemical applicatio...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/166548A1 |
Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a ...
|
|
WO/2022/169864A1 |
The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/106469A3 |
The present invention provides compounds of formula (I), for the treatment of an infection in warm-blooded animal caused by endoparasites, more preferably a helminthic infection, even more preferably a heartworm infection. Exemplary comp...
|
|
WO/2022/167867A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, autoimmune disease, solid o...
|
|
WO/2022/167627A1 |
The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds accord...
|
|
WO/2022/106902A3 |
Provided herein are benzenesulfonamide compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
|
|
WO/2022/166741A1 |
A macrocyclic compound containing a benzoheterocycle and acting as an EGFR kinase inhibitor. Specifically disclosed is a compound as represented by formula I or a pharmaceutically acceptable salt, a stereoisomer and a tautomer thereof, a...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/165114A1 |
The present invention relates to compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
|
|
WO/2022/164735A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fi...
|
|
WO/2022/061155A9 |
Compounds having activity as anti-cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or tautomer, thereof, wherein X, Y, R1, R2, R3 R4, R5 and L are as defined h...
|
|
WO/2022/161448A1 |
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infecti...
|
|
WO/2022/160661A1 |
The present application provides a nitrogen-containing compound and an electronic component comprising same, and an electronic apparatus, and relates to the technical field of organic electroluminescence. The nitrogen-containing compound...
|
|
WO/2022/164934A1 |
The present disclosure provides methods, compounds and compositions that are relevant to DNA-repair and DNA-repair proteins such as tyrosyl-DNA phosphodiesterase 1 (TDP1) and type I topoisomerase (TOP1).
|
|
WO/2022/160015A1 |
The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic...
|
|
WO/2022/164789A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2022/162034A1 |
The present invention provides compounds of formula I or II: (I) wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the ...
|
|
WO/2022/163377A1 |
Provided is a photosensitizer which has a specific structure, and has higher sensitivity than existing photosensitizers when light irradiation causes a rapid change from hydrophilicity to hydrophobicity. The present invention pertains to...
|
|
WO/2022/161507A1 |
Provided are a crystal form of Brepocitinib tosylate, and a preparation method, pharmaceutical composition, and use therefor.
|
|
WO/2022/164085A1 |
Provided are a pharmaceutical composition and a method that each use a maleate of a triazolopyrazine derivative. In an aspect, the pharmaceutical composition provided by the present invention exhibits improved storage stability and pharm...
|
|
WO/2022/165076A1 |
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
|
|
WO/2022/161462A1 |
A substituted morpholine derivative with a structure as shown in a formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use of the derivative.
|
|
WO/2022/161461A1 |
The present invention provides a series of compounds of an SOS1 inhibitor. Specifically disclosed are a compound of formula (I), a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and the sal...
|
|
WO/2022/163846A1 |
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another...
|
